Protocol

BMJ Open Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

Niels Adriaenssens ^(D), ¹ Beatrice Scholtes, ² Robin Bruyndonckx ^(D), ^{3,4} Jan Y Verbakel ^(D), ^{5,6} An De Sutter, ⁷ Stefan Heytens ^(D), ⁷ Ann Van den Bruel, ⁵ Isabelle Desombere, ⁸ Pierre Van Damme, ⁹ Herman Goossens, ⁴ Laëtitia Buret, ² Els Duysburgh, ¹⁰ Samuel Coenen ^(D), ^{1,4}

ABSTRACT

To cite: Adriaenssens N, Scholtes B, Bruyndonckx R, *et al.* Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol. *BMJ Open* 2022;**12**:e054688. doi:10.1136/ bmjopen-2021-054688

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2021-054688).

ED and SC contributed equally.

NA and BS are joint first authors.

Received 19 June 2021 Accepted 12 January 2022

Check for updates

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Niels Adriaenssens; niels.adriaenssens@ uantwerpen.be

Introduction National SARS-CoV-2 seroprevalence data provide essential information about population exposure to the virus and help predict the future course of the epidemic. Early cohort studies have suggested declines in levels of antibodies in individuals associated with, for example, illness severity, age and comorbidities. This protocol focuses on the seroprevalence among primary healthcare providers (PHCPs) in Belgium. PHCPs manage the vast majority of (COVID-19) patients and therefore play an essential role in the efficient organisation of healthcare. Currently, evidence is lacking on (1) how many PHCPs get infected with SARS-CoV-2 in Belgium, (2) the rate at which this happens, (3) their clinical spectrum, (4) their risk factors, (5) the effectiveness of the measures to prevent infection and (6) the accuracy of the serology-based point-of-care test (POCT) in a primary care setting.

Methods and analysis This study will be set up as a prospective cohort study. General practitioners (GPs) and other PHCPs (working in a GP practice) will be recruited via professional networks and professional media outlets to register online to participate. Registered GPs and other PHCPs will be asked at each testing point (n=9) to perform a capillary blood sample antibody POCT targeting IgM and IgG against the receptor-binding domain of SARS-CoV-2 and complete an online questionnaire. The primary outcomes are the prevalence and incidence of antibodies against SARS-CoV-2 in PHCPs during a 12-month follow-up period. Secondary outcomes include the longevity of antibodies against SARS-CoV-2.

Ethics and dissemination Ethical approval has been granted by the ethics committee of the University Hospital of Antwerp/University of Antwerp (Belgian registration number: 3002020000237). Alongside journal publications, dissemination activities include the publication of monthly reports to be shared with the participants and the general population through the publicly available website of the Belgian health authorities (Sciensano). **Trial registration number** NCT04779424.

Strengths and limitations of this study

- This large cohort study provides precise estimates of the prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers at the national level.
- This study uses a serology-based point-of-care test (POCT) validated in a laboratory setting and validates this POCT in a primary care setting.
- The POCT used targets IgM and IgG against the receptor-binding domain of SARS-CoV-2 and can therefore also provide valuable information in a vaccinated population.
- Regular online data collection provides timely data that can be compared with that of the general population and other population groups, for example, healthcare workers in hospitals and nursing homes.
- Missing data points, reduced POCT accuracy and the use of a convenience sample could limit the validity of the study results.

INTRODUCTION

As of 16 May 2021, SARS-CoV-2 has infected over 162 million people worldwide (over 1 030 000 in Belgium) and caused over 3.3 million deaths from COVID-19 worldwide (over 24 000 in Belgium).¹ COVID-19 is a lethal respiratory tract infection, but infection with SARS-CoV-2 can also be mild and even asymptomatic.

SARS-CoV-2 seroprevalence estimates provide essential information about population exposure to infection and help predict the future course of the epidemic.^{2 3} When setting up this study, seroprevalence studies in Iceland⁴ and Spain⁵ showed different levels of population antibody positivity, lasting up to at least 4 months in Iceland. In addition, early



Open access

cohort studies have suggested waning of antibody levels in individuals associated with, for example, illness severity, age and comorbidities.^{6–8} Meanwhile, other seroprevalence studies showed antibody positivity lasting up to 9 months.⁹¹⁰ For Belgium, Sciensano (the Belgian National Scientific Institute, www.sciensano.be) performs national seroprevalence studies of SARS-CoV-2 antibodies in several relevant populations including schools,¹¹ hospital personnel¹² and nursing homes.¹³

This protocol focuses on the seroprevalence among primary healthcare providers (PHCPs). They manage the vast majority of COVID-19 and other patients and therefore play an essential role in the efficient organisation of healthcare.^{14 15} Among the PHCPs, general practitioners (GPs), in particular, act as gatekeepers to the next levels of care. Therefore, preserving the capacity of GPs, together with that of their coworkers, throughout the COVID-19 epidemic is essential.¹⁶ In Belgium, this is particularly concerning, given the GP workforce consists of mainly older adults and is therefore at higher risk of COVID-19-related morbidity and mortality.¹⁷ In Italy, GPs represented up to 38% of the physicians who died from COVID-19 early on in the epidemic.¹⁸

However, current evidence is lacking on (1) how many PHCPs are infected by SARS-CoV-2 or have COVID-19 in Belgium, (2) the rate at which this occurs, (3) their clinical spectrum, (4) their risk factors, (5) the effectiveness of the measures to prevent this from happening and (6) the accuracy of the immunological serology-based pointof-care test (POCT) used by PHCPs.

During the COVID-19 crisis, POCTs have been developed to identify the presence of antibodies for SARS-CoV-2. Compared with laboratory tests, a valid easy-to-use POCT will speed up the availability of the test results for both the participants and the national health authorities. Furthermore, by using POCTs in this study, PHCPs will have the opportunity to become more familiar with this type of technology.

Sciensano has validated five POCTs using finger prick blood, identifying one test with appropriate sensitivity (92.9%) and specificity (96.3%) for use in seroprevalence studies.¹⁹ We use this POCT for the present study. It targets IgM and IgG against the receptor-binding domain of SARS-CoV-2 and can therefore also provide valuable information in a vaccinated population.

If (Belgian) primary care cannot be delivered safely, the COVID-19 epidemic will disrupt public health by failing to deliver non-COVID-19-related healthcare and will be unable to (continue to) support the next levels of care during the current epidemic. Therefore, we need to monitor their health and the effectiveness of, and the need for, infection prevention and control measures during epidemics. In addition, the follow-up of a cohort of PHCPs will help us to understand the duration and nature of antibodies generated in response to SARS-CoV-2 infection as well as those generated in response to vaccination.²⁰ Whether and for how long antibody response protects those infected with SARS-CoV-2 from

future infections or illness will determine the value of serological tests.²¹

Primary objectives

- ► Assess the prevalence of antibodies against SARS-CoV-2 among PHCPs (PHCPs=GPs and other PHCPs in their practice) in Belgium at timepoint 1 and at different timepoints during a 12-month follow-up period.
- Assess the monthly and annual incidence of antibodies against SARS-CoV-2 among PHCPs in Belgium during a 12-month follow-up period.

Secondary objectives

- Assess the longevity of the serological antibody response among seropositive PHCPs.
- Assess the proportion of asymptomatic cases among (new) cases (that develop during follow-up).
- ► Assess the determinants (risk and predictive factors) of SARS-CoV-2 infection in PHCPs.
- Validate the serology-based POCT in a primary care setting (phase III validation).
- ► Familiarise PHCPs with the use of serology-based POCTs.

Once vaccination of PCHPs starts, this study will take into account vaccination rates when reporting the seroprevalence and be able to assess waning of antibodies after vaccination.

METHODS AND ANALYSIS

The aim of this study was to broaden the knowledge on SARS-CoV-2 infection in Belgian primary care and to contribute to scientific research, health service and policy management supporting the fight against this epidemic.

Study population

Inclusion criteria

- Any GP working in Belgium (including those in professional training) currently working in primary care and any PHCP from the same GP practice who physically manages (examines, tests and treats) patients.
- Participants must be able to comply with the study protocol and provide informed consent to participate in the study.

Exclusion criteria

- Staff hired on a temporary (interim) basis will be excluded as follow-up over time will be compromised.
- Administrative staff or technical staff without any prolonged (longer than 15min) face-to-face contact with patients are not eligible.
- PHCPs who were not professionally active during the inclusion period will not be eligible.

Study design

This study will be set up as a prospective cohort study.

Recruitment

PHCPs will be recruited prior to the first and second testing points (registration will be possible between 15

November 2020 and 15 January 2021). PHCPs working in clinical practice in Belgium will be invited to register online for participation in this national epidemiological study and will be asked to invite the other PHCPs in their practice to do the same. We will emphasise that PHCPs that have already been diagnosed with COVID-19 are also eligible. Information about the study will be disseminated to GPs and PHCPs via professional organisations (Domus Medica and College de Médecine Générale), university networks across the country and through professional media channels. The convenience sample of participants will be checked to ensure that it is representative in terms of geographical and demographic qualities.²²

Data collection

On inclusion in the study, participants will be assigned a unique study code by the researchers, who will manage the key between these codes and the identification data. They will receive testing material at their place of work through regular mail. At the first testing timepoint (T1), they will receive an invitation by email (including a personalised link to an online questionnaire in French and Dutch) inviting them to

- 1. Autocollect a capillary blood sample and analyse it using the POCT (OrientGene).
- 2. Complete a baseline questionnaire through a secured online platform hosted by Sciensano (Limesurvey).

The baseline questionnaire at the first testing point will ask for their informed consent and will ask for information about

- ► The result of the POCT.
- Basic sociodemographic data (age, gender, composition of household, for example, presence of schoolaged children in the house).
- ▶ Professional data (practice patient size).
- Health status (pre-existing health conditions, regular medication use, presence of symptoms since the start of the epidemic, previous positive test results for COVID-19).
- Professional exposure (contact with confirmed cases, use of infection prevention and control measures).
- ► The availability of personal protective equipment (practice organisational aspects, delayed care for non-urgent conditions) (see online supplemental materials).

A follow-up questionnaire will be sent for each of the subsequent testing timepoints. In addition to the POCT result, it will collect information on

- ► The health status, including the presence of symptoms.
- Vaccination status (date of vaccination, type of vaccine, number of doses and presence of side effects).
- Professional exposure (contact with confirmed cases, use of infection prevention and control measures) (see online supplemental materials).

Phase III validation of the POCT

To validate the POCT, a subsample of participants will be asked to provide a serum sample. This subsample will be made up of all those participants who were seropositive for SARS-Cov-2 on the POCT at T1 and a random sample of participants who were seronegative at T1.

The participants will be sent material to collect the blood sample (Becton Dickinson Vacutainer SSTTM ii Advance; ref 368879) along with postal materials (in accordance with the UN 3373 packaging norms) and instructions on how to send it to the laboratory of clinical biology of the University Hospital of Antwerp (UZA) (a reference laboratory chosen by Sciensano). Participants will be asked to send their blood sample the same day it is taken, and analysis will be undertaken within 24 hours of reception. Analysis will be done with a reference standard using the following testing algorithm: serum samples will be tested first on the ELECSYS Anti-SARS-CoV-2 S assay (Roche, Basel, Switzerland). If the cut-off index is between 0.6 and 3.0, the sample will be tested on the ATELLICA IM SARS-CoV-2 assay (Siemens, Munich, Germany), and in case of discordant results, it will be tested on the LIAISON SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy) using a two out of three 'reference standards'. The analytical and clinical performance of these three commercially available, fully automated SARS-CoV-2 antibody assays was investigated at UZA, and the relevance of this testing algorithm was explained and illustrated (B Peeters, personal communication, 2020). Analytical performance of all three assays was acceptable and comparable with results found in other studies.^{23–26}

Participants of this subsample will receive a $\in 25$ voucher by way of compensation for the time and effort invested. The results of the serum sample will be communicated to participants via regular postal services.

Follow-up

The study will last 12 months. Epidemiological data collected through the online questionnaires and self-sampling using the POCT will occur monthly for 6 months with one sample collection at 9 months and the final one at 12 months (table 1). This corresponds to a total of nine testing timepoints. This number, however, will depend on the evolution of the epidemic. At each testing timepoint, participants will be asked to perform the POCT within a time frame of maximum 5 days. For the subsample providing a serum sample, participants will be asked to take the serum sample at the same time (just prior) to performing the POCT.

The result of the POCT will be entered as a variable in the online questionnaire.

Data analysis will be performed and reported after each relevant testing period and at the end of the study. All pseudonymised data collected will be stored securely by Sciensano for 10 years after completion of the study.

Sample size

This study aimed to include 5000 PHCPs with a 4 GPs to 1 other PHCP ratio considering the following sample size considerations regarding the different objectives of the proposed study.

Table 1 Timing	of data co	llection								
	T1	T2	Т3	T 4	T5	Т6	T7	Т8	Т9	Tota
	M0	M1	M2	M3	M4	M5	M6	M9	M12	9
POCT	Х	Х	Х	Х	Х	Х	Х	Х	Х	9
Baseline Q	Х									1
Follow-up Q		Х	Х	Х	Х	Х	Х	Х	Х	8
Serum		Х								1

M, month; POCT, point-of-care test; Q, questionnaire; T, testing point.

To estimate a prevalence ranging from 5% to 10%, the current estimates for SARS-CoV-2 seroprevalence in the general population and hospital care providers, with a precision ranging from 2% to 1% at a 95% confidence level, a sample size ranging from 504 to 3554 PHCPs is required (binomial 'exact' calculation), respectively. Since PHCPs will be clustered in their practices, we must correct the sample size. For an average of 2.5 PHCPs per practice (m) and an intracluster correlation of 0.2 (r), the design effect $(=1+(m-1)\times r)$ is 1.3. The corrected sample size ranges from 655 to 4620 PHCPs. Higher seroprevalence and non-response, both of which are to be expected, will reduce the precision of the estimates as will stratification by region or province. For example, with a sample size of 4620 PHCPs distributed equally over 11 strata, which corresponds to the number of provinces in Belgium (n=10) plus Brussels, the precision will range between 2.5% and 3.5% for a prevalence ranging from 5% to 10%, respectively.

Since multivariate prediction research for each determinant studied requires at least 10 subjects in the smallest category of the outcome variable to allow proper statistical modelling,^{27 28} a model including 25 determinants would require 250 seropositive participants, which corresponds to a 5% seroprevalence in 5000 or a 10% seroprevalence in 2500 PHCPs, not taking into account interaction terms in the model. The number of determinants that can be assessed in multivariable analysis to predict new cases will depend on the incidence. For example, to be able to assess 10 determinants would require 100 new cases or 3% new cases in 3600 PHCPs or 4700 PHCPs considering a design effect of 1.3. A lower incidence or lower sample size would further limit the number of determinants that can be modelled. Using more recently described methods to calculate the sample size required for developing a clinical prediction model would also require a sample size of substantially more than 2000 participants (n=2283, with 228 events and 9.1 events per predictor) to meet the four criteria described by Riley et al in case of a mean average prediction error of 0.025.²⁹

To estimate an incidence of 3% with a precision of 1% at a 95% confidence level, a sample size of 1212 PHCPs is required or 1576 PHCPs considering a design effect of 1.3 (4160 PHCPs to estimate an incidence of 2% with a precision of 0.5% and considering clustering).

To be able to validate the POCT's accuracy in the primary care setting, that is, to estimate the POCT's sensitivity (92.9%) with a lower limit of its 95% CI of 90% and its specificity (96.3%) with a lower limit of its 95% CI of 95%, a sample of 301 PHCPs seropositive on the reference standard (for sensitivity) and 810 PHCPs seronegative on the reference standard (for specificity) is required, which corresponds to for example 6% seroprevalence in 5022 PHCPs. To reduce the burden on the participants and the costs of the study, all those with a positive POCT and only a (random) sample of 900 PHCPs with a negative POCT will be assessed with the reference standard, and inverse probability weighting will be applied to correct for missing reference standard data by design.^{30–32}

A sample size of 5000 would also allow us to estimate the longevity of the antibody response among the PHCPs seropositive on the POCT. For example, starting from 300 PHCPs seropositive based on the POCT, a decrease of 10% in seroprevalence can be estimated with a precision of 4% at a 95% confidence level. Smaller decreases in seroprevalence and/or estimating with lower precision would require less than 5000 PHCPs to identify sufficient PHCPs seropositive on the POCT. Clustering will most likely not be an issue here since the waning of antibodies will most likely not be correlated among PHCPs working in the same practice.

Data protection

As described previously, epidemiological and serological data will be linked via a unique identifier code assigned to each participant. The same unique identifier code will be entered in each questionnaire, enabling the link for data analysis. This code will remain the same throughout the study. The key between the codes and the identification data of the participants will be kept in a secure and protected way by the principal investigators and the researchers, and destroyed on completion of the study. The personal data processing activities for the proposed research project will be submitted to the UAntwerpen Data Protection Office to review its completeness and compliance with the General Data Protection Regulation and to ask for formal approval. To control digital access only by authorised people on all devices (desktops, laptops, external drives, etc) at all locations (work, home and travel), complex passwords are used, and up-to-date antivirus and firewall protection is run. Using the Information and Communication Technology (ICT) services of UAntwerp, ULiège and Sciensano assures that the data will be backed up on a regular basis. The research team ensures that their personal computer system is always up-to-date and does not switch off the automatic installation of updates.

Data analysis

Data analysis will be done jointly by the principal investigators, researchers and team involved in this study with the University of Antwerp team taking the lead. Questionnaire responses will be coded. Data will be cleaned and validated; incomplete questionnaires will be manually checked to see if they can be included. Analysis will be mainly descriptive and done on R V.3.6.3 or equivalent.

Among others, the following indicators will be calculated, considering clustering of PHCPs in the same practice whenever appropriate:

- Seroprevalence of SARS-CoV-2: number of participants in whom presence of specific SARS-CoV-2 IgG is detected by the POCT/total number of participants tested with the POCT.
- Prevalence of reported COVID-19 cases: number of participants who self-report at baseline that SARS-CoV-2 infection (symptomatic and asymptomatic) was detected/total number of participants responding to the baseline questionnaire.
- ► SARS-CoV-2 seroconversion rate: number of participants in whom presence of specific SARS-CoV-2 IgM and/or IgG is detected by POCT at follow-up/total number of participants followed up not seroconverted before (based on prior POCT results), monthly during 12 months of follow-up.
- ► Incidence of reported COVID-19: number of participants who self-report new SARS-CoV-2 infections (symptomatic and asymptomatic) at follow-up/ total number of participants not yet infected before (based on prior self-reporting and POCT results) and responding to the follow-up questionnaire, monthly during 12 months of follow-up.
- ► SARS-CoV-2 antibody longevity: number of participants in whom presence of specific SARS-CoV-2 IgG is no longer detected by POCT at follow-up/total number of participants followed up seroconverted before (based on prior POCT results), monthly during 12 months of follow-up.

To assess determinants of SARS-CoV-2 seroprevalence and seroconversion in PHCPs, which include the availability and use of different preventive measures against SARS-CoV-2 infection, univariable and multivariable regression analyses, considering the clustering of participants at their practices, will be performed, for example, generalised estimating equations.³³ Model calibration will be assessed using calibration plots and the Hosmer-Lemeshow goodness-of-fit test.³⁴ Its discrimination will be estimated with the area under the receiver operating characteristic curve.




Figure 1 Participant flow. PHCP, primary healthcare provider; POCT, point-of-care test.

Data analysis phase III validation POCT

To validate the POCT in a primary care setting, we will estimate the following test characteristics:

- ► SARS-CoV-2 POCT sensitivity: number of participants testing positive on the SARS-CoV-2 POCT/total number of participants testing positive on the reference standard.
- SARS-CoV-2 POCT specificity: number of participants testing negative on the SARS-CoV-2 POCT/total number of participants testing negative on the reference standard.

These estimates will be corrected for missing reference standard data by inverse probability weighting to infer what the reference standard results might have been had the entire study sample been verified.³⁰⁻³² To show which participants are missing a reference standard result, a flowchart will be provided (figure 1).

Vaccination

The start of the vaccination of PHCPs during the study follow-up will provide the opportunity to monitor its progress (at regional level). Obviously, the PHCPs' vaccination status will be considered when assessing the primary and secondary outcomes of this study.

Bias and limitations

The study results will be based on a convenience sample. However, the sample will cover a large proportion of geographically well-distributed PHCPs.

Selection bias is possibly because of the 'late' start of the study: if all the most vulnerable PHCPs have already been infected at the time of the start of this study, then the incidence among the remaining PHCPs may be lower (because better immune system, more adherent to personal protection guidelines, etc). Hence, as in an earlier seroprevalence study,³⁵ we will explicitly ask for participation regardless of previous SARS-CoV-2 testing and test results. Insufficient sample size: due to the current heavy workload in Belgian primary care and time constraints, it might be difficult to recruit PHCPs into this study. However, we will aim for a security margin in the number of participants and have good experience in the earlier seroprevalence study.³⁵

Loss to follow-up or missing data will be possible, for example, if a participant becomes sick in between two data collection points without providing immediate samples and is isolated at home, or if a participant does not provide data at one point because of heavy workload, etc. In these cases, the participant will be invited to come back in the study and participate in the following data collection timepoint. However, in the current outbreak situation, PHCPs are supposedly very interested in knowing their infection status and therefore in participating in the study. Furthermore, their profession might make them more inclined to contribute to medical research. Finally, the duration of follow-up being relatively short, drop-out should be minimised. All efforts will be made to maintain the motivation of participants to participate at each timepoint by keeping them regularly updated of the results of the study, being attentive to questions and concerns: keeping communication to a minimum (to avoid overburdening them) and wherever possible communication with participants in their own language.³⁶

Underestimation and overestimation of the presence of SARS-CoV-2 among this population due to imperfect testing methods (imperfect sensitivity and specificity). However, this bias will be minimised by using best available POCT.¹⁹

Patient and public involvement

Patients or the public were not involved in the design, conduct, reporting or dissemination plans of our research. The research team, however, involved potential study subjects, that is, PHCPs.

Ethics and dissemination

Ethical approval has been granted by ethics committee of the UZA/University of Antwerp (Belgian registration number: 3002020000237). Anonymous study results will be made accessible and available as soon as possible after each testing point and at the end of the study to public health authorities involved in management of the COVID-19 epidemic in Belgium. This will be done through a policy brief or press release. Sciensano will coordinate the distribution of results. These results will also be published on a dedicated, public webpage of the Sciensano COVID-19 dashboard.³⁷

The general population will also be informed of the results through press communications. This will be done by the communication departments of the University of Antwerp and the University of Liège, Sciensano and the other study partners.

Scientific peer-reviewed publications (possible short communication, regular paper) will be prepared to add

to the body of evidence and availability for the global scientific community and public health decision makers.

Author affiliations

¹Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerpen, Belgium

²Département des Sciences Cliniques, University of Liege, Liege, Belgium ³Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute, Hasselt University, Hasselt, Belgium

⁴Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerpen, Belgium

 ⁵Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium
 ⁶Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK
 ⁷Department of Public Health and Primary Care, Ghent University, Gent, Belgium
 ⁸Department of Infectious Diseases in Humans, Sciensano, Brussel, Belgium
 ⁹Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerpen, Belgium

¹⁰Department of Epidemiology and Public Health, Sciensano, Brussel, Belgium

Correction notice This article has been corrected since it was published. Joint first authorship and equal contribution details have been added.

Twitter Jan Y Verbakel @jan_verbakel

Contributors The study concept and design were initiated by SC, NA, BS and ED and finalised with contributions from JYV, ADS, SH, AVdB, ID, PVD and HG. SC, NA and BS conducted registration and data collection. Analysis was performed by RB. NA prepared the first draft of the manuscript. All authors provided edits and critiqued the manuscript for intellectual content, approved the submitted version, were involved in the interpretation of data and agreed to be accountable for all aspects of the work.

Funding This work was supported by Sciensano (grant number 0Z8478).

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Niels Adriaenssens http://orcid.org/0000-0002-7957-1177 Robin Bruyndonckx http://orcid.org/0000-0002-4217-2869 Jan Y Verbakel http://orcid.org/0000-0002-7166-7211 Stefan Heytens http://orcid.org/0000-0003-1097-4987 Samuel Coenen http://orcid.org/0000-0002-1238-8052

REFERENCES

- 1 WHO coronavirus (COVID-19) Dashboard. Available: https://covid19. who.int [Accessed 17 May 2021].
- 2 Alter G, Seder R. The power of antibody-based surveillance. N Engl J Med 2020;383:1782–4.
- 3 Koopmans M, Haagmans B. Assessing the extent of SARS-CoV-2 circulation through serological studies. *Nat Med* 2020;26:1171–2.
- 4 Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020;383:1724–34.

Open access

- 5 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, *et al.* Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet* 2020;396:535–44.
- 6 Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee. JAMA 2020;324:1781–2.
- 7 Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020;26:1200–4.
- 8 Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020;383:1085–7.
- 9 Yao L, Wang G-L, Shen Y, et al. Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection. J Infect Dis 2021;224:586–94.
- Duysburgh E, Mortgat L, Barbezange C, et al. Persistence of IgG response to SARS-CoV-2. Lancet Infect Dis 2021;21:163–4.
- 11 Merckx J, Vermeulen M, Vandermeulen C. Prevalence and incidence of antibodies against SARS-CoV-2 in children and school staff measured for one year in Belgium: a sero-epidemiological prospective cohort study. Available: https://www.sciensano.be/nl/ biblio/prevalence-and-incidence-antibodies-against-sars-cov-2children-and-school-staff-measured-one-year [Accessed 17 May 2021].
- 12 Mortgat L, Arien K, Barbezange C. SARS-CoV-2 prevalence, seroprevalence and seroconversion among healthcare workers in Belgium during the 2020 Covid-19 outbreak: study protocol. Available: https://www.sciensano.be/nl/biblio/sars-cov-2-prevalenceseroprevalence-and-seroconversion-among-healthcare-workersbelgium-during-2020 [Accessed 17 May 2021].
- 13 De Sutter A, Heytens S, Duysburgh E. SARS-CoV-2 seroprevalence among nursing home staff and residents in Belgium: protocol. Available: https://www.sciensano.be/nl/biblio/sars-cov-2seroprevalence-among-nursing-home-staff-and-residents-belgiumprotocol [Accessed 17 May 2021].
- 14 Starfield B. Is primary care essential? Lancet 1994;344:1129-33.
- 15 Starfield B. Primary care and health. *JAMA* 1991;266:2268–71.
- 16 Phadke I, McKee Á, Conway JM, *et al.* Analysing how changes in the health status of healthcare workers affects epidemic outcomes. *Epidemiol Infect* 2021;149:E42.
- 17 Federale Overheidsdienst Volksgezondheid Veiligheid van de Voedselketen en Leefmilieu. Jaarstatistieken met betrekking tot de beoefenaars van gezondheidszorgberoepen in België, 2020. Available: https://overlegorganen.gezondheid.belgie.be/sites/default/ files/documents/statan_2019_-_nl.pdf [Accessed 17 May 2021].
- 18 Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri. Elenco dei Medici caduti nel corso dell'epidemia di Covid-19. Available: https://portale.fnomceo.it/elenco-dei-medicicaduti-nel-corso-dellepidemia-di-covid-19/ [Accessed 17 May 2021].
- 19 Triest D, Geebelen L, De Pauw R, et al. Performance of five rapid serological tests in mild-diseased subjects using finger prick blood for exposure assessment to SARS-CoV-2. J Clin Virol 2021;142:104897.

- 20 Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nat Commun* 2020;11:4704.
- 21 Gonzalez JM, Shelton WJ, Diaz-Vallejo M. Immunological assays for SARS-CoV-2: an analysis of available commercial tests to measure antigen and antibodies. *Open J Immunol* 2020;10:21–35.
- 22 Larremore DB, Fosdick BK, Bubar KM, et al. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. *Elife* 2021;10:e64206.
- 23 Favresse J, Eucher C, Elsen M, et al. Clinical performance of the Elecsys Electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. *Clin Chem* 2020;66:1104–6.
- 24 Egger M, Bundschuh C, Wiesinger K, et al. Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. *Clin Chim Acta* 2020;509:18–21.
- 25 Tré-Hardy M, Wilmet A, Beukinga I, et al. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. *Clin Chem Lab Med* 2020;58:1357–64.
- 26 Kohmer N, Westhaus S, Rühl C, et al. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J Clin Virol 2020;129:104480.
- 27 Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373–9.
- 28 Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med* 1996;15:361–87.
- 29 Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model. BMJ 2020;368:m441.
- 30 Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. *Stat Methods Med Res* 2013;22:278–95.
- 31 Naaktgeboren CA, de Groot JAH, Rutjes AWS, *et al.* Anticipating missing reference standard data when planning diagnostic accuracy studies. *BMJ* 2016;352:i402.
- 32 Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. *Biometrics* 1983;39:207–15.
- 33 LIANG K-YEE, Zeger SL. Longitudinal data analysis using generalized linear models. *Biometrika* 1986;73:13–22.
- Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
- 35 Mariën J, Ceulemans A, Bakokimi D, et al. Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium. Fam Pract 2022;39:92–8.
- 36 Abshire M, Dinglas VD, Cajita MIA, *et al.* Participant retention practices in longitudinal clinical research studies with high retention rates. *BMC Med Res Methodol* 2017;17:30.
- 37 Sciensano. Dashboard. Available: https://epistat.wiv-isp.be/covid/ covid-19.html [Accessed 17 May 2021].

11-6-2021

Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium -...

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium – consent and baseline T2 questionnaire

Dear Participant,

Thank you for your registration for the CHARMING study. We have provided you with your personal study materials for the first three testing time points.

Here we first ask for your formal consent to the study. All questions in the consent section need to be answered before you can proceed. Next we ask for your results on the rapid test, and questions about your health, household, practice and views on the SARS-COV2 pandemic.

If you have questions about CHARMING, please email us at covid-dmg@uliege.be (mailto:covid-dmg@uliege.be).

Many thanks in advance for carefully completing this questionnaire. We hope this will go smoothly for you.

The CHARMING study team

There are 74 questions in this survey.

E - Consent

Before giving your consent it is important that you have reviewed the information document about this study available in French **here**

(https://dox.uliege.be/index.php/s/n64T153cp07BOkG) and in Dutch here (https://dox.uliege.be/index.php/s/OYp4cllx8oxERBt).

https://surveys.sciensano.be/index.php/admin/printablesurvey/sa/index/surveyid/835947/lang/en

1/29



1 Your study code (C followed by 4 numbers; see our email of 25.01.2021 with your link to this questionnaire): *****

Please write your answer here:

2

I have received an information sheet (version 2.2, 26-11-2020). All my questions concerning this study have been answered satisfactorily. I was given sufficient time to reflect before agreeing to participate in this study. *

Please choose only one of the following:

🔵 Yes

3

My participation is voluntary. I have the right to withdraw my consent at any time without giving a reason. *

Please choose only one of the following:

🔵 Yes

4

In order to meet the needs of this study, I consent to the collection and use of my data (including the result of the rapid test). *

Please choose only one of the following:

🔵 Yes

5

I authorise the consultation of my data to the persons collaborating in this research (these persons are listed in the information form). *

Please choose only one of the following:

Yes

6

I agree that the data recorded in this study will be kept for 20 years and may be processed for future research on respiratory infections and coronaviruses. *

Please choose only one of the following:

Yes

7 I agree to provide a blood sample to validate the rapid test.

Please choose only one of the following:

Yes No

8 I agree to provide a blood sample to examine the T-cell response.

Please choose only one of the following:

Yes No

9

I agree that the blood samples taken in this study will be stored for 20 years and can be processed at a later date. *

Please choose only one of the following:



10 After this study, I agree to be approached for further research. *

Please choose **only one** of the following:

) Yes

🔵 No

11 I wish to participate in this survey. *

Please choose **only one** of the following:

🔵 Yes

Results of the rapid test

12 Date on which you carried out the rapid test (dd.mm.yyyy)? *

Please enter a date:

13 Did the control line "C" change from blue to red? If not, the test is invalid.

*

Please choose only one of the following:

🔵 Yes

🔵 No

*

14 Result of your quick test for IgG?

A red line visible next to G = positive (see figure).

Only answer this question if the following conditions are met: Answer was 'Yes' at question '13 [Q00013]' (Did the control line "C" change from blue to red? If not, the test is invalid.)

Please choose **only one** of the following:

) Positive

) Negative

) Unclear

11-6-2021	Sciensano surveys - Prevalence and incidence of	f antibodies against SARS-CoV-2 a	mong primary healthcare providers in Belgium
	e de la	i anabealee agailet er a te eet 2 a	meng primary meananeare premaere in Beigham

15 Result of your quick test for IgM?

A red line visible next to M = positive (see figure).

*

Only answer this question if the following conditions are met: Answer was 'Yes' at question '13 [Q00013]' (Did the control line "C" change from blue to red? If not, the test is invalid.)

Please choose only one of the following:

🔵 Positive

) Negative

🔵 Unclear

16 Date on which you completed this questionnaire (dd.mm.yyyy)? *

Please enter a date:

17 How many sealed tests do you have left after this testing time point? *

• Choose one of the following answers Please choose **only one** of the following:

) 0 sealed tests

-) 1 sealed test
-) 2 sealed tests
-) 3 sealed tests
-) 4 sealed tests
-) 5 sealed tests

Your health

18

Do you smoke? *

• If you choose 'not for_____ years' please also specify your choice in the accompanying text field.

• Only numbers may be entered in 'not for_____ years' accompanying text field. Please choose **only one** of the following:

🔵 Yes	
I have stopped smoking	

) I have never smoked

19 How many years ago did you stop smoking?

Only answer this question if the following conditions are met: Answer was 'I have stopped smoking' at question '18 [Q00018]' (Do you smoke?)

Please write your answer here:

years

20

How many alcoholic drinks do you consume per week?

Please choose **only one** of the following:

() > 20

6-2021	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgiu
	ave you been vaccinated against pneumococcus? * choose only one of the following:
 Ye No I de 	
	ave you been vaccinated against influenza for this er season (2020-2021)?
Please	choose only one of the following:
⊖ Ye	S
◯ No ◯ I de	on't know yet
Please	ave you been vaccinated against COVID-19? * choose only one of the following:
() Ye	

	Vhich vaccine did you receive? *
	nswer this question if the following conditions are met: r was 'Yes' at question '23 [Q00023]' (Have you been vaccinated against COVID-
Please	choose only one of the following:
O Pf	izer/BioNTech
Ом	oderna
	(ford/AstraZeneca
0	her
25 F	low many doses have you received? *
	nswer this question if the following conditions are met:
Only a	
Answe	r was 'Yes' at question '23 [Q00023]' (Have you been vaccinated against COVID-
Answe 19?)	r was 'Yes' at question '23 [Q00023]' (Have you been vaccinated against COVID-
Answe 19?) Please	
Answe 19?)	

Only answer this question if the following conditions are met: Answer was 'Yes' at question '23 [Q00023]' (Have you been vaccinated against COVID-19?)

Please enter a date:

27

Do you have one or more chronic diseases?

Please choose **only one** of the following:

\bigcirc	Yes
\bigcirc	res

) No

28 What chronic disease(s) do you have? (multiple answers possible) *

Only answer this question if the following conditions are met:

Answer was 'Yes' at question '27 [Q00027]' (Do you have one or more chronic diseases?)

Please choose all that apply:

Hypertension

Diabetes

Obesity

Other

29 Please list other chronic diseases

Only answer this question if the following conditions are met:

Answer was at question '28 [Q00028]' (What chronic disease(s) do you have? (multiple answers possible))

Please write your answer here:

	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers i
30 E	o you take medicines for chronic diseases? *
	nswer this question if the following conditions are met: r was 'Yes' at question '27 [Q00027]' (Do you have one or more chronic diseases?
Please	choose only one of the following:
) Ye	S
31 If	yes which ones? *
Only a	nswer this question if the following conditions are met: r was 'Yes' at question '30 [Q00030]' (Do you take medicines for chronic
Please	choose all that apply:
	CE inhibitors

Immunosuppressants

Corticosteroids (also inhalation)

NSAID

Other

32 Other medicines for chronic disease

Only answer this question if the following conditions are met: Answer was at question '31 [Q00031]' (If yes which ones?)

Please write your answer here:

33 Other medicines in the last six months

Only answer this question if the following conditions are met: Answer was 'Yes' at question ' [Q00034]' (Have you taken medicines other than those for chronic diseases in the last six months?)

Please write your answer here:

34 Have you taken medicines other than those for chronic diseases in the last six months? *

Please choose only one of the following:

🔵 Yes

) No

Your general practice

35 I work in general practice as... *

Please choose **only one** of the following:

) General practitioner

) General practitioner in training

) Other healthcare providers, e.g. nurse, dietician, ...

emental material	BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)	BN
11-6-2021	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belg	gium –
36 W	/hich year of your training are you in?	
-	nswer this question if the following conditions are met: r was 'General practitioner in training' at question '35 [Q00035]' (I work in general e as)	
Please	choose only one of the following:	
⊖ Ye	ar 1	
Ye	ar 2	
⊖ Ye	ar 3	
37 P	lease select your profession *	
Answe	nswer this question if the following conditions are met: r was 'Other healthcare providers, e.g. nurse, dietician,' at question '35 35]' (I work in general practice as)	

Please choose only one of the following:

Nurse	
O Psychologist	
Dietician	
◯ Speech therapist	
Other	

38 I have been doing this job for... *

Please choose only one of the following:

Less than 2 years

2 to 5 years

6 to 10 years

More than 10 years

https://surveys.sciensano.be/index.php/admin/printablesurvey/sa/index/surveyid/835947/lang/en

13/29

Please choose al	I that apply:
As CRA (coo	rdinating and advising doctor)
In a hospital	
In an instituti	on (e.g. psychiatry, care for the disabled,)
I don't have a	ny other activity
Other:	
	her healthcare professionals work in your nultiple answers possible) *
(1 1 /

41 What is the (estimated) number of patients assigned to your practice? *

Please write your answer here:

Nurse

Other:

Practice assistant None of the above

-...

	It is the (estimated) proportion of patients younger years of age (%) ? *
-	wer must be between 0 and 100 e your answer here:
%	
	t is the (estimated) proportion of patients over 65
	f age (%)? * wer must be between 0 and 100
-	e your answer here:
%	
increas	It is the estimated proportion of patients with ed benefits (%) ? * wer must be between 0 and 100
Please write	e your answer here:
%	
	t is the (estimated) proportion of patients with a $(0/2) = 1$
	on background (%) ? *

11-6-2021

Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium -...

46 What is the (estimated) proportion of patients who do not speak Dutch, French or German (%)?*

Please write your answer here:

%

Your household

47 What is the composition of your household? *
Each answer must be at least 0 Please write your answer(s) here:
How many family members does your household include, including yourself?
How many children attend a crèche (less than 2.5 years) ?
How many children attend pre-school (2,5 to 6 years)?
How many children attend primary school (typically 6 to 12 years)?
How many children attend secondary school (typically 12 - 18 years?
Leve menu bevecheld members are university/cellers students (tyricelly ared ever 10
How many household members are university/college students (typically aged over 18 years) AND sleeping in the family home more than 3 nights per week?
How many household members (typically over 18 years) in employment AND sleeping in
the family home more than 3 nights per week?

11-6-2021

Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium -...

48 Is your partner employed in healthcare with patient contact? *

Please choose only one of the following:

🔵 Yes

) No

) Not applicable

49 How many household members had complaints this year that are compatible with COVID-19, including yourself? *

Please write your answer here:

-...

Answe	nswer this question if the following conditions are met: er was greater than or equal to '1' at question '49 [Q00049]' (How many household ers had complaints this year that are compatible with COVID-19, including elf?)
Please	e choose all that apply:
∏ I d	lidn't have any complaints
 Co	bugh
 He	eadache
So	pre throat
E Fe	ever
Sł	nortness of breath
🗌 Rı	unny nose
M	uscle pain
Lc	oss of sense of smell
Lc	oss of taste
Ge	eneral weakness/ fatigue
Na	ausea/ vomiting
🗌 Di	arrhoea
Otl	her:

Please write your answer here:

https://surveys.sciensano.be/index.php/admin/printablesurvey/sa/index/surveyid/835947/lang/en

18/29

11-6-2021	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium
	· · · · · · · · · · · · · · · · · · ·

52 How often have you been tested (except for the research purposes)? *

Please write your answer here:

times

53 How many days have you spent in quarantine? * Please choose only one of the following:					
◯ 0 days					
◯ up to 5 days					
◯ up to 7 days					
◯ up to 10 days					
◯ up to 14 days					
◯ up to 20 days					
◯ more than 20 days					
54 Have you ever tested positive for COVID-19? *					
Please choose only one of the following:					
Yes					
◯ No					

11-6-202

1	Sciensano surveys - Pr	revalence and incidence o	of antibodies against SARS-Co	V-2 among primary healthca	are providers in Belgium –

55 If you tested positive, when was the positive sample taken? *

Only answer this question if the following conditions are met:

Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID-19?)

Please choose only one of the following:

February

) March

() April

) May

🔵 June

🔵 July

August

🔵 September

October

November

- () December
- 🔵 January 2021

56 if you know the exact date of the positive sample enter it here:

Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID-19?)

Please enter a date:

mental material	placed on this supplemental material which has been supplied by the author(s)	В
11-6-2021	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in E	3elgium –
	he positive test result which s) was/were used? (multiple answers possible) *	
-	nswer this question if the following conditions are met: r was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID-	
Please	choose all that apply:	
Ra	CR (for virus detection) apid test (for virus detection) bod sample (for antibody detection)	
	apid test (for antibody detection)	

Other:

58 If you tested positive, who was the suspected source of the infection? *

Only answer this question if the following conditions are met:

Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID-19?)

Please choose all that apply:

Patient

Co-worker

Family member

Other:

Sector 2 Sector 2 Prevalence and incidence of antibodies against SARS-Cov2 among primary healthcare providers in Registration Sector 2	al material	BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)	
you have? * Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID- 19?) Please choose all that apply: Symptomatic treatment of pain, fever and other complaints Hydroxychloroquine Antibiotics No treatment Other:	6-2021	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Bel	gium
Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID- 19?) Please choose all that apply: Symptomatic treatment of pain, fever and other complaints Hydroxychloroquine Antibiotics No treatment Other: 60 If you were admitted for COVID-19, how many days did you spend in hospital? (if you were not admitted to hospital put '0') * Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID- 19?) Please write your answer here:			
Symptomatic treatment of pain, fever and other complaints Hydroxychloroquine Antibiotics No treatment Other:	Answer		
Hydroxychloroquine Antibiotics No treatment Other: 60 If you were admitted for COVID-19, how many days did you spend in hospital? (if you were not admitted to hospital put '0') * Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID-19?) Please write your answer here:	Please	choose all that apply:	
Antibiotics No treatment Other: 60 If you were admitted for COVID-19, how many days did you spend in hospital? (if you were not admitted to hospital put '0') * Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID- 19?) Please write your answer here:	Syn	nptomatic treatment of pain, fever and other complaints	
No treatment Other: 60 If you were admitted for COVID-19, how many days did you spend in hospital? (if you were not admitted to hospital put '0') * Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID-19?) Please write your answer here:	Hyc	Iroxychloroquine	
60 If you were admitted for COVID-19, how many days did you spend in hospital? (if you were not admitted to hospital put '0') * Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID- 19?) Please write your answer here:	Ant	ibiotics	
60 If you were admitted for COVID-19, how many days did you spend in hospital? (if you were not admitted to hospital put '0') * Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID- 19?) Please write your answer here:	No	treatment	
If you were admitted for COVID-19, how many days did you spend in hospital? (if you were not admitted to hospital put '0') * Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID- 19?) Please write your answer here:	Othe	er:	
Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID- 19?) Please write your answer here:	lf you you s	pend in hospital?	
Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID- 19?) Please write your answer here:	(if yo	u were not admitted to hospital put '0') *	
	Answer		
dava	Please	write your answer here:	
dava			

61

If you were admitted for COVID-19, how many days did you stay in intensive care? (if you were not admitted to intensive care put '0') *

Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [Q00054]' (Have you ever tested positive for COVID-19?)

Please write your answer here:

days

62 How many household members have tested positive for COVID-19, **not** including yourself? *

Please write your answer here:

63 How many household members have been admitted to hospital for (suspected) COVID-19, **not** including yourself?

Please write your answer here:

64 How many household members have been treated for (suspected) COVID-19, **not** including yourself? *

Please write your answer here:

11-6-2021

Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium -...

Risk factors for COVID-19

65 Have you continued to work since the outbreak? *

Please choose **only one** of the following:

🔵 Yes

() No

66 Have you been in physical contact with patients with confirmed COVID-19 since the outbreak? *

Please choose only one of the following:

() Yes

🔵 No

67 If so, how many? *

Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [Q00066]' (Have you been in physical contact with patients with confirmed COVID-19 since the outbreak?)

Please choose only one of the following:

) 1 - 5 patients

- \bigcirc 6 10 patients
-) 11 15 patients
-) 16 20 patients
-) > 20 patients

	ave you lacked protective equipment since the eak? *
Please	choose only one of the following:
) Yes	
69 If	so which equipment? (multiple answers possible) *
Only ar Answer	swer this question if the following conditions are met: was 'Yes' at question '68 [Q00068]' (Have you lacked protective equipment since preak?)
Please	choose all that apply:
Glo	ves
 Sui	gical mouth mask
 Oth	er mouth mask (FFP2 or FFP3)
	ety goggles
 Apı	on / body protection
Oth	er:
patie	available, which protective material do you use in nts with (suspected) COVID-19)? (multiple answers ble) *
-	choose all that apply:
Glo	ves
	gical mouth mask
	er mouth mask (FFP2 or FFP3)
	ety goggles
Sat	ety goggies

11-6-2021	Sciensano surveys - Prevalence and incidence of antibo	dies against SARS CoV/2 among pr	imany healthcare providers in Belgium
11-0-2021	Sciensario surveys - Frevalence and incidence of antibo	ules against or to -cov-z among pi	inary nearincare providers in Deigium –

71 If available, what protective material do you use with your other patients? (multiple answers possible) *	
Please choose all that apply:	
 Gloves Surgical mouth mask Other mouth mask (FFP2 or FFP3) safety goggles Apron/body protection Other: 	

72 Have y	/ou	participated i	n the	COVID	patient	triage? *

Please choose only one of the following:

) Yes

) No

73 If so, how many patients	did you physically examine
who subsequently turned ou	ut to be COVID-19 positive? *

Only answer this question if the following conditions are met: Answer was 'Yes' at question '72 [Q00072]' (Have you participated in the COVID patient triage?)

Please choose only one of the following:

0 patients
1 - 5 patients
6 - 10 patients
11 - 15 patients
16 - 20 patients
> 20 patients

74

Indicate to what extent you agree with the following statements

(1= totally disagree; 5= totally agree): *

Please choose the appropriate response for each item:

	1	2	3	4	5
The personal protection equipment that I use, protects me sufficiently against more contagious variants of SARS-CoV-2.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
A temporary ban on non-essential international travel is needed.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
I am sure I am already infected with COVID-19.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
I will certainly be infected with COVID- 19 during this epidemic.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
I am afraid I am contaminating my relatives.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
The guidelines for primary care are clearly communicated.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
The guidelines for primary care are scientifically based.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
The Belgian healthcare system is strong enough to cope with this epidemic.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
The testing capacity in Belgium is sufficient.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Rapid diagnostic tests are relevant for general practice.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Rapid diagnostic tests for SARS-CoV-2 viral detection are manageable for general practice.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc

	1	2	3	4	5
The measures imposed by the government are sufficient.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Everyone should wear a mask if they go outdoors.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
I have every confidence in the scientific COVID-19 expert committee.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Most of my patients follow the rules of 'social distancing'.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	0
Most of my patients adhere to hygiene rules.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	0
La plupart de mes patients symptomatiques respectent les règles de quarantaine.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	0
This period is more stressful than during a busy flu period.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	0
I want to get the COVID-19 vaccination as soon as it is available.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc

Thank you very much for completing this questionnaire.

You will shortly receive an email that will explain what your test result means. We will send you an overview of your consent to participate in the study in the coming weeks.

The CHARMING study team



https://surveys.sciensano.be/index.php/admin/printablesurvey/sa/index/surveyid/835947/lang/en

28/29

Submit your survey. Thank you for completing this survey.

https://surveys.sciensano.be/index.php/admin/printablesurvey/sa/index/surveyid/835947/lang/en

29/29

Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium - ...

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium - Followup questionnaire February 2021

Dear Participant,

Thank you for your participation in CHARMING. This follow-up questionnaire refers to the period since the last testing period.

Many thanks in advance for carefully completing this questionnaire. We hope this will go smoothly for you.

The CHARMING study team

PS If you have questions about CHARMING, please email us at covid-dmg@uliege.be (mailto:covid-dmg@uliege.be).



There are 46 questions in this survey.

Part 1

1 Your personal study code (C followed by 4 numbers; see our email of 26.02.2021 with your link to this questionnaire): *****

Please write your answer here:

Part 2

Instructions on how to perform the rapid test can be found in French **here** (https://dox.uliege.be/index.php/s/1duglah08HN8YIr) and in Dutch **here** (https://dox.uliege.be/index.php/s/hqqiswSGBxKw3yf). Short instruction videos are available here:

- French test on yourself : https://vimeo.com/492411023/7b2bedb700 (https://vimeo.com/492411023/7b2bedb700)

- French test on someone else: https://vimeo.com/492427669/b42bb624b6 (https://vimeo.com/492427669/b42bb624b6)

- Dutch test on yourself: https://vimeo.com/492430777/92626224d1

(https://vimeo.com/492430777/92626224d1)

- Dutch test on someone else : https://vimeo.com/492428827/d565f20bc2

(https://vimeo.com/492428827/d565f20bc2)

2 Date on which you carried out the rapid test (dd.mm.yyyy)? *

Please enter a date:

3 Did the control line "C" change from blue to red? If not, the test is invalid.

*

Please choose **only one** of the following:

) Yes

🔵 No

4 Result of your quick test for IgG?
A red line visible next to G = positive (see figure).
Please choose only one of the following:
 Positive Negative Unclear
5 Result of your quick test for IgM?
A red line visible next to M = positive (see figure).
Please choose only one of the following:
OPositive
◯ Negative
OUnclear
6 Date on which you completed this questionnaire (dd.mm.yyyy)? * Please enter a date:

Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium - ...

7 How many sealed tests do you have left after this testing time point? *

Please choose only one of the following:

) 0 sealed tests

-) 1 sealed test
-) 2 sealed tests
-) 3 sealed tests
-) 4 sealed tests
-) 5 sealed tests

Part 3

8 Since your first testing period (end December 2020 or end January 2021), how many days have you spent in quarantine? *
Please choose only one of the following:
◯ 0 days
◯ up to 5 days
◯ up to 7 days
◯ up to 10 days
◯ up to 14 days
◯ up to 20 days
◯ more than 20 days

11-6-2021	Sciensano surveys - Prevalence and incidence o	f antibodies against SARS-CoV-2 amo	ng primary healthcare providers in Belgium

9 Since **your first** testing period (end December 2020 or end January 2021), how often have you been tested for COVID-19 (except for research purposes)? *

Please write your answer here:

times

10 I work in general practice as * Please choose only one of the following:
 General practitioner General practitioner in training Other healthcare providers, e.g. nurse, dietician,
11 Please select your profession * Please choose only one of the following:
Please choose only one of the following:
Please choose only one of the following:
Please choose only one of the following:

- ...

1-6-2021	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belg
12 5	Since the last testing period I have also worked *
Please	e choose all that apply:
	s CRA (coordinating and advising doctor)
	a hospital
l In	an institution (e.g. psychiatry, care for the disabled,)
	lon't have any other activity
Ot	her:

Part 4

13 Since the last testing phase of CHARMING how many family members had complaints that are compatible with COVID-19, including yourself? *

	they? (multiple answers possible) *
lease	choose all that apply:
ld	idn't have any complaints
Co	ugh
He	adache
So	re throat
Fe	ver
Sh	ortness of breath
Ru	nny nose
Μι	iscle pain
Lo	ss of sense of smell
Lo	ss of taste
Ge	eneral weakness/ fatigue
Na	usea/ vomiting
Dia	arrhoea
Oth	

15 Since the last testing period how many family members, including yourself, have been tested for COVID-19 (excluding tests for research purposes)?

◯ Yes ◯ No	
17	
	sitive test result which s/were used? (multiple answers possible) *
	all that apply:
PCR (for v	irus detection)
Rapid test	(for virus detection)
	ple (for antibody detection)
Rapid test	(for antibody detection)
Other:	

	se all that apply:
	natic treatment of pain, fever and other complaints chloroquine
Antibiot	
No trea	nent
Other:	
nfectior	
	se all that apply:
Please choo	
Patient	er
Patient	er

days

22

If you were admitted for COVID-19, how many days did you stay in intensive care? (if you were not admitted to intensive care put '0') *

Please write your answer here:

days

23 Since the last testing period how many family members have tested positive for COVID-19, **not** including yourself?

Please write your answer here:

24 Since the last testing period how many family members have been admitted to hospital for (suspected) COVID-19, **not** including yourself? *

Please write your answer here:

25 Since the last testing period how many family members have been treated for (suspected) COVID-19, **not** including yourself? *

Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium - ...

Part 5

26 Have you continued to work in primary care since the **last** testing period? *

Please choose only one of the following:

🔵 Yes

) No

27 Have you been in physical contact with patients with confirmed COVID-19 since the last testing period? *

Please choose only one of the following:

🔵 Yes

🔵 No

28 If so, how many? *

Please choose only one of the following:

) 1 - 5 patients

─ 6 - 10 patients

) 11 - 15 patients

- 16 20 patients
- > 20 patients

29 Have you lacked protective equipment since the last testing period? * Please choose only one of the following:	6-2021	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgiun
Please choose all that apply: Gloves Surgical mouth mask Other mouth mask (FFP2 or FFP3) Safety goggles Apron / body protection Other: 31 If available, which protective material have you used since the last testing period in patients with (suspected) COVID-19)? (multiple answers possible) * Please choose all that apply: Gloves Surgical mouth mask Other mouth mask (FFP2 or FFP3) Safety goggles Apron/body protection	testi Please	ng period? *
Surgical mouth mask Other mouth mask (FFP2 or FFP3) Safety goggles Apron / body protection Other: 31 If available, which protective material have you used since the last testing period in patients with (suspected) COVID-19)? (multiple answers possible) * Please choose all that apply: Gloves Surgical mouth mask Other mouth mask (FFP2 or FFP3) Safety goggles Apron/body protection		
Other: 31 If available, which protective material have you used since the last testing period in patients with (suspected) COVID-19)? (multiple answers possible) * Please choose all that apply: Gloves Surgical mouth mask Other mouth mask (FFP2 or FFP3) Safety goggles Apron/body protection	GI St Of Sa	oves irgical mouth mask her mouth mask (FFP2 or FFP3) ifety goggles
<pre>since the last testing period in patients with (suspected) COVID-19)? (multiple answers possible) * Please choose all that apply: Gloves Surgical mouth mask Other mouth mask (FFP2 or FFP3) Safety goggles Apron/body protection </pre>		
 Surgical mouth mask Other mouth mask (FFP2 or FFP3) Safety goggles Apron/body protection 	sinc CO\	e the last testing period in patients with (suspected) /ID-19)? (multiple answers possible) *
 Other mouth mask (FFP2 or FFP3) Safety goggles Apron/body protection 	GI	oves
Safety goggles Apron/body protection		
Apron/body protection		
Other:		
	Oti	ner:

11-6-2021	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium
11-0-2021	Sciensario surveys - Prevalence and incidence of antibodies against SARS-Cov-2 antibig primary neartificare providers in beiginn

32 If available, what protective material have you used with your other patients? (multiple answers possible) * Please choose all that apply: Gloves Surgical mouth mask Other mouth mask (FFP2 or FFP3) safety goggles Apron/body protection
33 Have you participated in the COVID patient triage since the last testing period? * Please choose only one of the following: Yes No
 34 If so, how many patients did you physically examine who subsequently turned out to be COVID-19 positive? * Please choose only one of the following: 0 patients 1 - 5 patients 6 - 10 patients 11 - 15 patients 16 - 20 patients > 20 patients

Yes	ose only one of the following:
) No	
36 Whic	ch vaccine did you receive? *
	ose only one of the following:
) Pfizer/F	BioNTech
) Moderr	
	AstraZeneca
) Other	
Other	
87 How	many doses have you received? *
	many doses have you received? *
_	se only one of the following.
) 1 dose) 2 dose	
) z uose.	,
	n did you receive the first dose of the vaccine .yyyy)? *
	· / [[[]

39 Did you experience side-effects after receiving the **first** dose? *

Please choose **only one** of the following:

◯ No side-effects

) Negligible side-effects

) Mild side-effects

) Moderate side-effects

) Severe side-effects

40 For how many days did you experience the following side-effects after the **first** dose (if you did not experience the side-effect put '0'): *

41 What other moderate or severe side-effects did you experience after receiving the **first** dose?

Please write your answer here:

42 When did you receive the **second** dose of the vaccine (dd.mm.yyyy)? *

Please enter a date:

21	Sciensano surveys - Prevalence and incidence o	f antibodies against SARS-CoV-2 ar	mong primary healthcare providers in Belgium

43 Did you experience side-effects after receiving the **second** dose? *

Please choose only one of the following:

◯ No side-effects

) Negligible side-effects

) Mild side-effects

) Moderate side-effects

) Severe side-effects

44 For how many days after receiving the **second** dose of the vaccine did you experience the following side-effects (if you did not experience the side-effect put '0')? *

45 What other moderate or severe side-effects did you experience after receiving the **second** dose?

46

Indicate to what extent you agree with the following statements

(1= totally disagree; 5= totally agree): *

Please choose the appropriate response for each item:

	1	2	3	4	5
The personal protection equipment that I use, protects me sufficiently against more contagious variants of SARS-CoV-2.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
A temporary ban on non-essential international travel is still needed.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
The Belgian healthcare system is strong enough to cope with this epidemic.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
The testing capacity in Belgium is sufficient.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Rapid diagnostic tests are relevant for general practice.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Rapid diagnostic tests for SARS-CoV-2 viral detection are manageable for general practice.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
The measures imposed by the government are sufficient.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Everyone should wear a mask when they work inside with other people.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
I have every confidence in the scientific COVID-19 expert committee.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Most of my patients follow the rules of 'social distancing'.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Most of my patients adhere to hygiene rules.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc

11-6-2021	Sciensano surveys - Prevalence and incidence of antib	Sciensano surveys - Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium				

	1	2	3	4	5
Most of my symptomatic patients respect the quarantine rules.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
This period is more stressful than during a busy flu period.	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
For health care personnel the COVID- 19 vaccination should be obligatory.	0	\bigcirc	\bigcirc	0	\bigcirc

Thank you very much for completing this questionnaire.

You will shortly receive an email that will explain what your test result means.

If you experience side-effects after receiving the vaccination you can report them officially here:

In Dutch: https://www.fagg.be/nl/bijwerking (https://www.fagg.be/nl/bijwerking) In French: https://www.afmps.be/fr/effet_indesirable (https://www.afmps.be/fr/effet_indesirable)

The CHARMING study team



21.03.2021 - 20:58

Submit your survey. Thank you for completing this survey.

https://surveys.sciensano.be/index.php/admin/printablesurvey/sa/index/surveyid/369690/lang/en

18/18